DrugPatentWatch Database Preview
EDEX Drug Profile
When do Edex patents expire, and when can generic versions of Edex launch?
Edex is a drug marketed by Auxilium Pharms Llc and is included in one NDA.
The generic ingredient in EDEX is alprostadil. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the alprostadil profile page.
Summary for EDEX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 78 |
| Patent Applications: | 2,520 |
| Drug Prices: | Drug price information for EDEX |
| DailyMed Link: | EDEX at DailyMed |
Pharmacology for EDEX
| Drug Class | Prostaglandin Analog Prostaglandin E1 Agonist |
| Mechanism of Action | Prostaglandin Receptor Agonists |
| Physiological Effect | Genitourinary Arterial Vasodilation Venous Vasodilation |
Synonyms for EDEX
| (-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoate |
| (-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoic acid |
| (-)-Protaglandin E1 |
| (+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoate |
| (+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoic acid |
| (11?,13E,15S)-11,15-Dihydroxy-9-oxo-prost-13-en-1-oic acid |
| (11alpha,12alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid |
| (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid |
| (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid |
| (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid |
| (13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoate |
| (13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoic acid |
| (13E)-(15S)-11,15-dihydroxy-9-oxoprost-13-enoate |
| (13E)-(15S)-11,15-dihydroxy-9-oxoprost-13-enoic acid |
| (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate |
| (13e)-(15s)-11alpha,15-dihydroxy-9-oxoprost-13-enoic acid |
| (1R,2R,3R)-3-Hydroxy-2-((E)-(3S)-3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid |
| 11,15-Dihydroxy-9-oxoprost-13-en-1-oate |
| 11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid |
| 11,15-dihydroxy-9-oxoprost-13-en-1-oic acid (ACD/Name 4.0) |
| 119314-69-1 |
| 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid |
| 22299-37-2 |
| 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate |
| 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid |
| 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid |
| 50-83-9 |
| 50865-30-0 |
| 7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)heptanoic acid |
| 7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)heptanoic acid |
| 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid |
| 7-[(1r,3r)-3-Hydroxy-2-[(1e,3s)-3-Hydroxyoct-1-En-1-Yl]-5-Oxocyclopentyl]heptanoic Acid |
| 7-[5-((1E)(3S)-3-hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]hepta noic acid |
| 745-65-3 |
| 745P653 |
| 9-oxo-11R,15S-dihydroxy-13E-prostaenoic acid |
| AB0014134 |
| AB00514004 |
| AB00514004_09 |
| AB00514004-06 |
| AB00514004-08 |
| AB2000131 |
| AC-6095 |
| AC1NQXHQ |
| AI3-62116 |
| AKOS015961103 |
| Alista |
| alprostadil |
| Alprostadil (JP17/USP/INN) |
| Alprostadil [USAN:USP:INN:BAN:JAN] |
| Alprostadil Prostoglandin E1 |
| Alprostadil, European Pharmacopoeia (EP) Reference Standard |
| Alprostadil, meets USP testing specifications |
| Alprostadil, United States Pharmacopeia (USP) Reference Standard |
| Alprostadil(Caverject) |
| Alprostadil(usan) |
| Alprostadilum |
| Alprostadilum [INN-Latin] |
| Alprox-TD |
| AS-16360 |
| B2154 |
| BC205461 |
| BCP01740 |
| BCP9000277 |
| BDBM50101853 |
| Befar |
| Befar (TN) |
| BG0025 |
| BIDD:GT0747 |
| BML1-F06 |
| BPBio1_001293 |
| BRD-K52459643-001-06-0 |
| BRD-K52459643-001-10-2 |
| BRD-K52459643-001-17-7 |
| BSPBio_001175 |
| BSPBio_001488 |
| C04741 |
| CAS-745-65-3 |
| Caverject |
| Caverject Impulse |
| CCG-101188 |
| CHEBI:15544 |
| CHEMBL495 |
| CPD000112594 |
| CS-1905 |
| Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, (-)- |
| Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, l- |
| D00180 |
| DSSTox_CID_2578 |
| DSSTox_GSID_22578 |
| DSSTox_RID_76640 |
| DTXSID9022578 |
| EINECS 212-017-2 |
| EX-A1411 |
| F5TD010360 |
| FemLife |
| Femprox |
| GMVPRGQOIOIIMI-DWKJAMRDSA-N |
| GTPL1882 |
| HEI-507 |
| HMS1361K10 |
| HMS1571K17 |
| HMS1791K10 |
| HMS1989K10 |
| HMS2052L11 |
| HMS2090L08 |
| HMS2098K17 |
| HMS3268I09 |
| HMS3402K10 |
| HMS3648O17 |
| HMS3715K17 |
| HY-B0131 |
| IDI1_033958 |
| K274 |
| l-3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid |
| l-PGE1 |
| l-Prostaglandin E1 |
| Lipoprost |
| Liprostin |
| LMFA03010134 |
| MFCD00077860 |
| Minprog |
| MLS000758964 |
| MLS001424250 |
| MolPort-003-939-183 |
| MR 256 |
| MR-256 |
| Muse |
| NC00438 |
| NCGC00016535-01 |
| NCGC00025234-02 |
| NCGC00025234-03 |
| NCGC00025234-04 |
| NCGC00025234-05 |
| NSC 165559 |
| ONO 1608 |
| PGE-1 |
| PGE1 |
| PGE1 Oligomer |
| PGE1, Prostaglandin E1, powder |
| PGE1;Prostaglandin E1 |
| PGE1alpha |
| Prestwick2_001018 |
| Prestwick3_001018 |
| Prink |
| Prink (TN) |
| Promostan |
| Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11.alpha.,13E,15S)- |
| Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)- |
| Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer |
| Prostaglandin E1 |
| Prostaglandin E1, >=98% (HPLC), synthetic |
| Prostaglandin E1, >=99.0% (TLC) |
| Prostaglandin E1, 98+% |
| Prostaglandin E1, powder, gamma-irradiated, BioXtra, suitable for cell culture |
| Prostaglandin E1, synthetic, powder, BioReagent, suitable for cell culture |
| Prostaglandin E1; PGE1 |
| Prostaglandin E1;Edex;Muse;Liprostin;Caverject |
| Prostaglandin-E1 |
| Prostaglandine E |
| Prostandin |
| Prostavasin |
| Prostin VR |
| Prostin VR Pediatric |
| Prostin VR pediatric (TN) |
| Prostivas |
| RayVa |
| RP17688 |
| s1508 |
| SAM001246840 |
| SAM001246845 |
| SAM001247093 |
| SCHEMBL33317 |
| SMP2_000271 |
| SMR000112594 |
| SR-01000597593 |
| SR-01000597593-1 |
| SR-01000597593-5 |
| SR-01000597593-6 |
| SR-01000946253 |
| SR-01000946253-1 |
| ST50826271 |
| Sugiran |
| SYN3025 |
| Topiglan |
| Tox21_110482 |
| U 10136 |
| U-10,136 |
| U-10136 |
| UNII-F5TD010360 |
| Vasaprostan |
| Viridal |
| Vitaros |
| Vitaros (TN) |
| W-104416 |
| XPG |
| ZINC3813088 |
US Patents and Regulatory Information for EDEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Auxilium Pharms Llc | EDEX | alprostadil | INJECTABLE;INJECTION | 020649-001 | Jun 12, 1997 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Auxilium Pharms Llc | EDEX | alprostadil | INJECTABLE;INJECTION | 020649-007 | Jul 30, 1998 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Auxilium Pharms Llc | EDEX | alprostadil | INJECTABLE;INJECTION | 020649-003 | Jun 12, 1997 | AP | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||
| Auxilium Pharms Llc | EDEX | alprostadil | INJECTABLE;INJECTION | 020649-002 | Jun 12, 1997 | AP | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||
| Auxilium Pharms Llc | EDEX | alprostadil | INJECTABLE;INJECTION | 020649-005 | Jul 30, 1998 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Auxilium Pharms Llc | EDEX | alprostadil | INJECTABLE;INJECTION | 020649-004 | Jun 12, 1997 | AP | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
